Sunshine Lake Pharma Co., Ltd.

This study tests a new drug called HEC73543 (Clifutinib) against standard chemotherapy in 324 adults with a specific type of acute myeloid leukemia (FLT3-ITD) that has come back or not responded to treatment. The goal is to see if the new drug helps people live longer and achieve…

This study tests an experimental drug called HEC585 in people with progressive fibrosing interstitial lung disease, a condition where lung tissue becomes scarred and breathing gets harder over time. About 110 adults will receive either a low dose, high dose, or a placebo for 24 w…

This study tests a new tablet called HEC585 for people with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and makes breathing hard. About 472 adults aged 40 to 80 will take either HEC585, a placebo, or an existing drug (pirfenidone) for 52 weeks. The ma…

This study tests a new oral drug, HEC169096, that blocks a cancer-driving protein called RET. It is for people with advanced thyroid cancer, non-small cell lung cancer, or other solid tumors that have not responded to standard treatments. The trial has two phases: first to find t…

This study tests a new drug, mitizodone phosphate, to see if it can safely reduce symptoms of major depression. About 600 adults with moderate to severe depression will receive either the drug or a placebo for 8 weeks. The goal is to find the best dose and confirm whether the dru…

This early-stage study tests a new medicine called HEC169584 in 96 healthy adults aged 18 to 45. The goal is to check if the drug is safe and how the body processes it. This is a first step before testing it in people with non-alcoholic steatohepatitis (NASH), a type of fatty liv…

This early-phase study is testing whether a single shot of HEC-151 is safe and how the body processes it. About 81 healthy Chinese men aged 18-45 will take part. The goal is to check for side effects and measure drug levels in the blood, not to treat any disease.

This early-phase study tests the safety and how the body processes a new injection called HEC-007. It involves 126 healthy adults and overweight or obese volunteers. The goal is to check for side effects and measure drug levels, not to treat any disease.